Vericel (VCEL) Q1 2026 Earnings Transcript

Vericel posted record Q1 revenue of $68.4 million, up 30% year over year, with gross margin expanding to 72% and adjusted EBITDA rising 195% to $9.6 million. Management raised 2026 guidance for total revenue to $326 million-$336 million, MACI to $282 million-$288 million, and Burn Care to $44 million-$48 million, helped by strong MACI and Epicel execution and expected BARDA-related NexoBrid revenue. The FDA approved MACI manufacturing at the new facility, and Vericel secured a BARDA contract worth up to $197 million, supporting longer-term growth and international expansion.

Analysis

VCEL is transitioning from a single-product growth story to a more durable multi-engine compounding model, and the market is likely still underappreciating how much operating leverage comes from the mix shift rather than headline growth alone. The critical second-order effect is that MACI’s expanded sales force and Arthro adoption are doing two things at once: increasing near-term implant conversion and widening the installed base that can generate repeat biopsies over the next 12-24 months. That creates a self-reinforcing funnel, so the quarter’s margin expansion may prove conservative if conversion continues to tick higher without proportionate selling expense growth.

The BARDA award changes the burn franchise from a lumpy specialty business into something closer to a partially funded strategic countermeasure platform. That matters because procurement revenue is only the visible wedge; the real option value sits in VMI, stockpile expansion, and trauma-indication development, which can extend revenue well beyond the current guidance window and potentially de-risk the burn salesforce economics. This also gives VCEL a stronger negotiating position with hospitals by embedding NexoBrid into preparedness workflows rather than purely elective utilization.

The main risk is not near-term demand, but the market’s tendency to capitalize this as if current growth is already the terminal run rate. If orthopedic procedure volumes soften or a competitor earns reimbursement in a narrower segment, the first pressure point is likely not revenue but incremental conversion efficiency at the margin. Over the next 1-2 quarters, the cleanest tell will be whether biopsy growth and implant pull-through stay aligned; if they diverge, the multiple can compress quickly because this is still a high-expectation story.

Contrarian angle: consensus may be over-focusing on whether Q2 matches Q1 rather than on the quality of the revenue base. The better bear case is not a growth miss, but that investors are underestimating how much of 2026’s upside is already being pulled forward by a very strong Q1 and the BARDA headline, leaving less room for incremental beats. Still, if management is right that conversion and surgeon adoption are improving, the stock likely deserves a higher duration multiple than a typical medtech compounder.

Key Decisions for Investors

• Long VCEL on 3-6 month horizon into Q2/Q3 prints; risk/reward favors upside if biopsy-to-implant conversion stays elevated and BARDA revenue starts on schedule. Use a partial position now and add on any post-earnings consolidation rather than chasing strength.
• Buy VCEL call spreads 6-9 months out to express upside to guidance re-rating with defined risk; the setup is more about multiple expansion on sustained execution than a one-quarter earnings pop.
• Pair trade: long VCEL / short a broader medtech basket or orthopedics-sensitive names if procedure-volume worries intensify; VCEL’s internal funnel is less exposed than peers to general utilization noise.
• If already long, trim only on evidence that Q2 biopsy growth decelerates while implant growth lags; that would be the earliest sign the sales-force expansion is saturating and the multiple should compress.
• Watch for a pullback after the BARDA enthusiasm fades; if the stock de-rates on no fundamental change, that is a higher-conviction add point because the optionality is not yet fully embedded in consensus estimates.